AJMC January 21, 2022
Payer perspective regarding updates to coverage for comprehensive genomic profiling, becoming more widely used in oncology practice.
Bruce Feinberg, DO: Eugean, from a payer perspective, it takes me back to the argument we used to use in categorizing lymphomas, when it was all histology. We were going from good and bad, fast and slow. At some point, we got to over 70. There were always the lumpers and the splitters. The lumper said, “We just need to differentiate how they’re clinically different.” The splitters said, “No, there’s nuance. You need to have that nuance.” From a payer perspective, do they want the lump or the split? How important is the nuance? How are they responding to this increasing precision aspect,...
Today's Sponsors
Today's Sponsor